HRH1
ENSG00000196639
Target class
GPCR
Chromosome
3
Approved drugs
60
Clinical candidates (approved and in development)
72
- Approved drugs
- 60
- Clinical candidates (approved and in development)
- 72
- Chemical probe available
- Yes
- Target name
- HRH1
- Gene name
- Histamine receptor H1
- Gene symbol
- HRH1
- Protein name
- Histamine H1 receptor (H1-R) (H1R) (HH1R)
- Gene biotype
- Protein coding
- Gene family
- Histamine receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 36
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 18.2
- Tissue specificity (Gini)
- 0.517
- Tissue specificity (tau)
- 0.809
- KEGG gene identifiers
- hsa:3269
- Protein interaction confidence
- 0.812875
- Protein interaction partners
- 8
- R-HSA-390650
- R-HSA-416476
- End position
- 11263557
- Start position
- 11137093
- Chromosome
- 3
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein .
- Plasma membrane
Publication evidence
- PubMed 21697825
- Tissue specificity (tau)
- 0.808605
- Expression inequality (Gini)
- 0.51733
Expression in transcripts per million
- Artery - Aorta
- 18.2
- Nerve - Tibial
- 13.56
- Cells - Cultured fibroblasts
- 12.55
- Artery - Tibial
- 10.35
- Artery - Coronary
- 8.14
Expression in transcripts per million
- Artery - Aorta18.2
- Nerve - Tibial13.56
- Cells - Cultured fibroblasts12.55
- Artery - Tibial10.35
- Artery - Coronary8.14
- Cervix - Endocervix7.74
- Adipose - Subcutaneous7.54
- Vagina7.5
- Fallopian Tube7.32
- Cervix - Ectocervix6.32
- Bladder6.12
- Skin - Sun Exposed (Lower leg)5.71
- Adipose - Visceral (Omentum)5.63
- Lung5.43
- Colon - Sigmoid5.31
- Brain - Frontal Cortex (BA9)5.25
- Skin - Not Sun Exposed (Suprapubic)5.1
- Uterus4.79
- Brain - Anterior cingulate cortex (BA24)4.71
- Breast - Mammary Tissue4.65
- Ovary4.6
- Brain - Cortex4.24
- Esophagus - Muscularis4.07
- Colon - Transverse4.01
- Esophagus - Gastroesophageal Junction3.66
And 29 more, listed on the interactive page.
- GO:0007186
- GO:0071420
Cellular components
- GO:0005886
- GO:0004969
- GO:0005515
increased convulsions
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased convulsions
- nervous system
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264increased heart rate
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased heart rate
- nervous system
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264increased body weight
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased body weight
- nervous system
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264bronchoconstriction
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: bronchoconstriction
- nervous system
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264decreased inflammation
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased inflammation
- nervous system
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264flushing
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: flushing
- nervous system
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264increased QTc interval
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased QTc interval
- nervous system
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264decreased/increased blood pressure
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased/increased blood pressure
- nervous system
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264decreased gastrointestinal transit
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased gastrointestinal transit
- nervous system
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264increased pain
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased pain
- nervous system
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264inflammation
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: inflammation
- nervous system
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264skin rash
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: skin rash
- nervous system
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264increased drinking
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased drinking
- nervous system
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264sedation
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: sedation
- nervous system
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264decreased convulsions
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased convulsions
- nervous system
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264abdominal cramps
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: abdominal cramps
- nervous system
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264sweating
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: sweating
- nervous system
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264cardiac arrhythmia
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: cardiac arrhythmia
- nervous system
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264decreased pain
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased pain
- nervous system
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264scratching
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: scratching
- nervous system
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264decreased blood pressure
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased blood pressure
- nervous system
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264diarrhea
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: diarrhea
- nervous system
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264facial swelling
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: facial swelling
- nervous system
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264increased locomotor activity
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased locomotor activity
- nervous system
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264increased sleep
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased sleep
- nervous system
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264
And 1 more, listed on the interactive page.
decreased blood pressure
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: decreased blood pressure
- cardiovascular system
- immune
PubMed 23197038increased body weight
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: increased body weight
- cardiovascular system
- immune
PubMed 23197038receptor binding
Studies
- biochemical: NVS_GPCR_hH1, is one of one assay component(s) measured or calculated from the NVS_GPCR_hH1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.
Biological samples
- cell-free
Evidence sourceallergic responses of flare, flush and wheal
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: allergic responses of flare, flush and wheal
- cardiovascular system
- immune
PubMed 23197038sedation
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: sedation
- cardiovascular system
- immune
PubMed 23197038bronchoconstriction
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: bronchoconstriction
- cardiovascular system
- immune
PubMed 23197038decreased allergic responses
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: decreased allergic responses
- cardiovascular system
- immune
PubMed 23197038
Related records
Trials (1,075)
- : Vascular Function in Health and Disease
- "THINK Trial: Treatment of Headache With IntraNasal Ketamine: A Randomized Controlled Trial Evaluating the Efficacy of Intranasal Ketamine Versus Standard Therapy in the Management of Primary Headache Syndromes in the Emergency Department"
- 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
- 3-D Visualization of the Anti-Obstructive Effect of Levocetirizine
- 4"S" - Seasonal Symptoms Suppression Study
- 723/726 Proof of Concept Study in Allergen Challenge Chamber in Hannover
- A 6-Month Efficacy and Safety Study of Org 50081 in Adult Patients With Chronic Primary Insomnia (21106/P05701/MK-8265-002)
- A Bioequivalence Study of Domestic (Made in China) and Imported Mizolastine Tablets in Healthy Volunteers
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
- A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.5/1000 mg in Healthy Male Volunteers
- A Clinical Trial Evaluating the Role of Systemic Antihistamine Therapy in the Reduction of Adverse Effects Associated With Topical 5-aminolevulinic Acid Photodynamic Therapy
- A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
- A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
- A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)
Drugs (113)
- Acrivastine Histamine H1 receptor antagonist
- Alcaftadine Histamine H1 receptor antagonist
- Antazoline Histamine H1 receptor antagonist
- Antazoline phosphate Histamine H1 receptor antagonist
- Astemizole Histamine H1 receptor antagonist
- Azatadine Histamine H1 receptor antagonist
- Azatadine maleate Histamine H1 receptor antagonist
- Azelastine Histamine H1 receptor antagonist
- Azelastine hydrochloride Histamine H1 receptor antagonist
- Bepotastine Histamine H1 receptor antagonist
- Bepotastine besylate Histamine H1 receptor antagonist
- Betahistine Histamine H1 receptor agonist
- Bilastine Histamine H1 receptor inverse agonist
- Bromodiphenhydramine Histamine H1 receptor antagonist
- Bromodiphenhydramine hydrochloride Histamine H1 receptor antagonist
- Brompheniramine Histamine H1 receptor antagonist
- Brompheniramine maleate Histamine H1 receptor antagonist
- Buclizine Histamine H1 receptor antagonist
- Buclizine hydrochloride Histamine H1 receptor antagonist
- Carbinoxamine Histamine H1 receptor antagonist